Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration (HpXeMRCal)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02316379 |
|
Recruitment Status :
Recruiting
First Posted : December 12, 2014
Last Update Posted : December 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Respiratory Disorders | Drug: Hyperpolarized 129 Xenon Device: MRI | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration |
| Study Start Date : | February 2015 |
| Estimated Primary Completion Date : | August 24, 2023 |
| Estimated Study Completion Date : | August 24, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Hyperpolarized 129 Xenon
Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
|
Drug: Hyperpolarized 129 Xenon
During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
Other Name: HP 129 Xe Device: MRI |
- Correlation of ventilated volume predictions obtained with 129Xe MRI vs. 1H MRI [ Time Frame: Day 1 ]quantify the measurement agreement between the ventilated volume of healthy lungs predicted via 129 Xe MRI and the ventilated volume of the pleural cavity predicted via proton MRI
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adults ages 18 years and older
- Participant must be able to hold their breath for up to 16 seconds
Exclusion Criteria:
- History of heart defect
- Pregnancy or positive pregnancy test
- History of uncontrolled asthma defined for this study as requiring use of rescue inhaler ≥ 2 times in past month.
- Symptoms of respiratory infection (loose or productive cough or wheeze), chest tightness, or sinus infection within past week.
- Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula.
- Participant is claustrophobic and unable to tolerate the imaging.
- Standard MRI exclusions (metal, implants).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02316379
| Contact: Carrie Stevens, BS | 513-636-9973 | Carrie.Stevens@cchmc.org | |
| Contact: Kelly Thornton, BS | 513-636-0604 | Kelly.Thornton@cchmc.org |
| United States, Ohio | |
| Cincinnati Children's Hospital Medical Center | Recruiting |
| Cincinnati, Ohio, United States, 45229 | |
| Contact: Jason C Woods, Ph.D 513-803-4463 jason.woods@cchmc.org | |
| Principal Investigator: | Jason C Woods, Ph.D. | Children's Hospital Medical Center, Cincinnati |
| Responsible Party: | Children's Hospital Medical Center, Cincinnati |
| ClinicalTrials.gov Identifier: | NCT02316379 |
| Other Study ID Numbers: |
2014-7643 IND 123577 ( Other Identifier: FDA ) |
| First Posted: | December 12, 2014 Key Record Dates |
| Last Update Posted: | December 19, 2020 |
| Last Verified: | December 2020 |
|
Respiratory |
|
Respiration Disorders Respiratory Tract Diseases Xenon Anesthetics, Inhalation |
Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |

